$4.51
0.10[2.27%]
Last update: 2:10PM Get Real Time Here
BioCryst Pharma
(NASDAQ:BCRX)BioCryst Pharma Stock (NASDAQ:BCRX), Analyst Ratings, Price Targets, Predictions
BioCryst Pharmaceuticals Inc has a consensus price target of $13.92, established from looking at the 38 latest analyst ratings. The last 3 analyst ratings were released from Needham, Needham, and JP Morgan on April 10, 2024, January 8, 2024, and November 20, 2023. With an average price target of $11.33 between Needham, Needham, and JP Morgan, there's an implied 158.16% upside for BioCryst Pharmaceuticals Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Needham
JP Morgan
RBC Capital
Jefferies
HC Wainwright & Co.
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for BioCryst Pharma
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/10/2024 | BCRX | Buy Now | BioCryst Pharma | $4.39 | 173.35% | Needham | Serge Belanger | → $12 | Reiterates | Buy → Buy | Get Alert |
| 01/08/2024 | BCRX | Buy Now | BioCryst Pharma | $4.39 | 173.35% | Needham | Serge Belanger | → $12 | Reiterates | Buy → Buy | Get Alert |
| 11/20/2023 | BCRX | Buy Now | BioCryst Pharma | $4.39 | 127.79% | JP Morgan | Jessica Fye | → $10 | Reinstates | → Overweight | Get Alert |
| 11/06/2023 | BCRX | Buy Now | BioCryst Pharma | $4.39 | 173.35% | Needham | Serge Belanger | → $12 | Reiterates | Buy → Buy | Get Alert |
| 09/25/2023 | BCRX | Buy Now | BioCryst Pharma | $4.39 | 127.79% | RBC Capital | Brian Abrahams | → $10 | Reiterates | Outperform → Outperform | Get Alert |
| 09/18/2023 | BCRX | Buy Now | BioCryst Pharma | $4.39 | 127.79% | RBC Capital | Brian Abrahams | $9 → $10 | Upgrade | Sector Perform → Outperform | Get Alert |
| 08/04/2023 | BCRX | Buy Now | BioCryst Pharma | $4.39 | 105.01% | RBC Capital | Brian Abrahams | $8 → $9 | Maintains | Sector Perform | Get Alert |
| 08/04/2023 | BCRX | Buy Now | BioCryst Pharma | $4.39 | 150.57% | Jefferies | Maury Raycroft | → $11 | Upgrade | Hold → Buy | Get Alert |
| 08/04/2023 | BCRX | Buy Now | BioCryst Pharma | $4.39 | 583.37% | HC Wainwright & Co. | Andrew Fein | → $30 | Reiterates | Buy → Buy | Get Alert |
| 08/03/2023 | BCRX | Buy Now | BioCryst Pharma | $4.39 | 173.35% | Needham | Serge Belanger | $14 → $12 | Reiterates | → Buy | Get Alert |
| 07/13/2023 | BCRX | Buy Now | BioCryst Pharma | $4.39 | 127.79% | B of A Securities | Tazeen Ahmad | → $10 | Upgrade | Neutral → Buy | Get Alert |
| 05/04/2023 | BCRX | Buy Now | BioCryst Pharma | $4.39 | 105.01% | RBC Capital | Brian Abrahams | → $9 | Reiterates | → Sector Perform | Get Alert |
| 05/04/2023 | BCRX | Buy Now | BioCryst Pharma | $4.39 | 218.91% | Needham | Serge Belanger | → $14 | Reiterates | → Buy | Get Alert |
| 04/20/2023 | BCRX | Buy Now | BioCryst Pharma | $4.39 | 127.79% | Evercore ISI Group | Liisa Bayko | $13 → $10 | Maintains | Outperform | Get Alert |
| 04/20/2023 | BCRX | Buy Now | BioCryst Pharma | $4.39 | 218.91% | Needham | Serge Belanger | → $14 | Reiterates | → Buy | Get Alert |
| 03/14/2023 | BCRX | Buy Now | BioCryst Pharma | $4.39 | 127.79% | RBC Capital | Brian Abrahams | → $10 | Reiterates | → Sector Perform | Get Alert |
| 02/22/2023 | BCRX | Buy Now | BioCryst Pharma | $4.39 | 264.46% | JMP Securities | Jonathan Wolleben | → $16 | Reiterates | → Market Outperform | Get Alert |
| 02/22/2023 | BCRX | Buy Now | BioCryst Pharma | $4.39 | 218.91% | Needham | Serge Belanger | → $14 | Upgrade | Hold → Buy | Get Alert |
| 02/22/2023 | BCRX | Buy Now | BioCryst Pharma | $4.39 | 583.37% | HC Wainwright & Co. | Andrew Fein | → $30 | Reiterates | → Buy | Get Alert |
FAQ
What is the target price for BioCryst Pharma (BCRX)?
The latest price target for BioCryst Pharma (NASDAQ: BCRX) was reported by Needham on April 10, 2024. The analyst firm set a price target for $12.00 expecting BCRX to rise to within 12 months (a possible 166.08% upside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for BioCryst Pharma (BCRX)?
The latest analyst rating for BioCryst Pharma (NASDAQ: BCRX) was provided by Needham, and BioCryst Pharma reiterated their buy rating.
When was the last upgrade for BioCryst Pharma (BCRX)?
The last upgrade for BioCryst Pharmaceuticals Inc happened on September 18, 2023 when RBC Capital raised their price target to $10. RBC Capital previously had a sector perform for BioCryst Pharmaceuticals Inc.
When was the last downgrade for BioCryst Pharma (BCRX)?
The last downgrade for BioCryst Pharmaceuticals Inc happened on August 8, 2022 when Oppenheimer changed their price target from N/A to N/A for BioCryst Pharmaceuticals Inc.
When is the next analyst rating going to be posted or updated for BioCryst Pharma (BCRX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioCryst Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioCryst Pharma was filed on April 10, 2024 so you should expect the next rating to be made available sometime around April 10, 2025.
Is the Analyst Rating BioCryst Pharma (BCRX) correct?
While ratings are subjective and will change, the latest BioCryst Pharma (BCRX) rating was a reiterated with a price target of $0.00 to $12.00. The current price BioCryst Pharma (BCRX) is trading at is $4.51, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.